Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study

Basit Öğe Kaydı
dc.authorid0000-0001-8554-7651
dc.authorid0000-0001-8945-2385
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorGüçlü, Ertu?rul
dc.contributor.authorArslan, Ferhat
dc.contributor.authorKoçak, Funda
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorÖzer, Serdar
dc.contributor.authorTuranlı, Münevver
dc.contributor.authorMert, Ali
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:52Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:52Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractObjective: To compare responses to tenofovir (TDF) and entecavir (ETV) therapy. Methods: This was a multicenter retrospective study including treatment-naïve patients with chronic hepatitis B (CHB) who received TDF or ETV. The primary end-points were undetectable HBV-DNA at 48 weeks and serological and biochemical responses. Results: Out of 195 CHB patients, 90 (46%) received TDF and 105 (54%) received ETV; 72% were male, their mean age was 43. ±. 12 years, and the mean duration of treatment was 30.2. ±. 15.7 months. Hepatitis B e antigen (HBeAg) seropositivity was 32% in the TDF group and 34% in the ETV group. HBeAg seroconversion rates in HBeAg-positive patients were 24% in the TDF group and 39% in the ETV group; the difference was not significant (. p=. 0.2). The mean time to alanine aminotransferase (ALT) normalization and rates of ALT normalization at 3, 6, 12, 18, and 24 months were similar in the two groups (. p > 0.05). The mean time to undetectable HBV-DNA levels in the TDF and ETV groups was 11.5. ±. 8.9 and 12.9. ±. 10.8 months, respectively (. p=. 0.32). A significantly greater decline in HBV-DNA levels at 12 and 18 months was observed in the TDF group (. p=. 0.02 and p=. 0.03, respectively). Seven (7%) patients on ETV therapy had virological breakthrough (. p=. 0.01). Only one patient in each group had hepatitis B surface antigen (HBsAg) clearance. None of the patients developed decompensation or hepatocellular carcinoma during treatment. Conclusions: The two drugs appear to have similar efficacy in CHB patients. However, 7% of patients on ETV therapy had virological breakthrough, while none of the patients on TDF therapy did.
dc.identifier.citationBatırel, A., Güçlü, E., Arslan, F., Koçak, F., Karabay, O., Özer, S., Turanlı, M. ve Mert, A. (2014). Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study. International Journal of Infectious Diseases, 28, 153-159. https://dx.doi.org/10.1016/j.ijid.2014.09.004
dc.identifier.doi10.1016/j.ijid.2014.09.004
dc.identifier.endpage159
dc.identifier.issn1201-9712
dc.identifier.scopusqualityQ1
dc.identifier.startpage153
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijid.2014.09.004
dc.identifier.urihttps://hdl.handle.net/20.500.12511/974
dc.identifier.volume28
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Unported*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/*
dc.subjectChronic Hepatitis B
dc.subjectEntecavir
dc.subjectHBV
dc.subjectTenofovir
dc.subjectTreatment
dc.titleComparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Arslan, Ferhat-2014.pdf
Boyut:
697.66 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu